SGRY Shareholders: Amparo Law Firm PLLC Is Investigating Whether Surgery Partners's $23.50-Per-Share Sale to HealthSpan Partners Delivers the Best Value for Shareholders
Key Highlights
- ➤HealthSpan Partners agreed to acquire Surgery Partners for $23.50 per share in cash
- ➤Transaction carries approximately $5.7 billion enterprise value, company-stated
- ➤Bain Capital affiliates will roll shares into acquiring-entity equity instead of receiving cash
- ➤Bain Capital owns approximately 39% of outstanding shares and agreed to vote for transaction
- ➤Shareholder vote has not been scheduled; closing is expected in first quarter of 2027
Expert Statements
Bob Amirian, Founding Partner of Amparo Law Firm PLLC
“Whether $23.50 per share is the best price shareholders could obtain, and whether shareholders may have claims for additional value.”
Bob Amirian, Founding Partner of Amparo Law Firm PLLC
“How the board ran the sale process and whether it looked for other buyers.”
Bob Amirian, Founding Partner of Amparo Law Firm PLLC
“The financial advisors' fees and any ties they have to the buyer.”
Bob Amirian, Founding Partner of Amparo Law Firm PLLC
“Whether the proxy statement gives you every fact Section 14(a) requires so you can judge that price before you vote.”
New York, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Attorney Advertising
Amparo Law Firm PLLC, through its Amparo Investor Rights practice, is investigating whether $23.50 per share is the best price Surgery Partners, Inc. (Nasdaq: SGRY) shareholders could obtain, whether the board ran a sale process designed to get it, and whether shareholders may have claims for additional value. We are also investigating whether the proxy statement gives you every fact Section 14(a) requires so you can judge that price before you vote. The proposed take-private is by HealthSpan Partners.
Get started
Create a free account to read the full story.
